Inverted urothelial papilloma. Is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?

John C. Cheville, Kevin Wu, Thomas J. Sebo, Liang Cheng, Darren Riehle, Christine M. Lohse, V. Shane Pankratz

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

BACKGROUND. Inverted urothelial papilloma is an unusual neoplasm of the urinary tract. Although the association between inverted urothelial papilloma and urothelial carcinoma is not entirely dear, many studies indicate that patients with inverted papilloma are at increased risk for the development of urothelial carcinoma. In addition, aneuploid inverted papillomas have been associated with the subsequent development of urothelial carcinoma. The objective of this study was to determine whether ploidy, MIB-1 proliferative activity, or p53 protein staining in inverted papilloma were predictive of urothelial carcinoma. METHODS. Fifty-one cases of inverted papilloma were retrieved from the Tissue Registry of the Mayo Clinic. Clinical records were reviewed for patient age, length of follow-up, and history of urothelial carcinoma (defined as carcinoma prior to, concurrent with, or subsequent to the diagnosis of inverted papilloma). DNA ploidy analysis was determined using Feulgen stained sections from paraffin embedded tissues using an image analysis system. Quantitation of MIB-1 proliferative activity and p53 immunostaining was determined similarly using immunoperoxidase stained sections from paraffin embedded tissues. RESULTS. The mean age at diagnosis of inverted papilloma was 63.9 years (range, 37-87 years), and there were 39 men and 12 women. Patients were followed for a mean of 56.5 months (range, 1- 252 months). Tumors ranged in size from 02 to 4.3 cm (mean, 0.9 cm). Eight patients (15.7%) had a prior, concurrent, or subsequent noninvasive World Health Organization and International Society of Urologic Pathology (WHO/ISUP) papillary neoplasm of low malignant potential or papillary, carcinoma of low grade (formerly WHO Grade 1 or 2 papillary urothelial carcinoma). Inverted papillomas in patients with a history of urothelial carcinoma were all diploid and had a mean MIB-1 activity of 6.3% (range, 0.04-24.8%) and mean p53 protein staining of 12.6% (range, 0.5-24.9%). These inverted papillomas ranged in size from 0.3 to 1.0 cm (mean, 0.5 cm). Inverted papillomas in patients without a history of urothelial carcinoma were aneuploid in 6 cases (14.3%) and diploid in the remaining cases. These inverted papillomas had a mean MIB-1 activity of 1.6% (range, 0.06-9.0%) and mean p53 protein staining of 9.7% (range, 0.05-38.0%). Tumor size ranged from 0.2 to 4.3 cm (mean, 1.0 cm). There were no statistically significant differences in MIB-1 activity, p53 protein staining, ploidy, and morphologic features between inverted papillomas in patients with and without a history of urothelial carcinoma. CONCLUSIONS. Ploidy, MIB-1 proliferative activity, and p53 immunostaning in inverted urothelial papilloma were not useful in identifying patients who had a history of urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)632-636
Number of pages5
JournalCancer
Volume88
Issue number3
DOIs
StatePublished - Feb 1 2000
Externally publishedYes

Fingerprint

Inverted Papilloma
Ploidies
Carcinoma
Proteins
Staining and Labeling
Papillary Carcinoma
Aneuploidy
Diploidy
Paraffin
Urologic Neoplasms
Neoplasms

Keywords

  • Aneuploidy
  • Inverted urothelial papilloma
  • P53
  • Proliferation
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inverted urothelial papilloma. Is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma? / Cheville, John C.; Wu, Kevin; Sebo, Thomas J.; Cheng, Liang; Riehle, Darren; Lohse, Christine M.; Pankratz, V. Shane.

In: Cancer, Vol. 88, No. 3, 01.02.2000, p. 632-636.

Research output: Contribution to journalArticle

Cheville, John C. ; Wu, Kevin ; Sebo, Thomas J. ; Cheng, Liang ; Riehle, Darren ; Lohse, Christine M. ; Pankratz, V. Shane. / Inverted urothelial papilloma. Is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?. In: Cancer. 2000 ; Vol. 88, No. 3. pp. 632-636.
@article{58cc1a5b001f4ff0abf6055601193bee,
title = "Inverted urothelial papilloma. Is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?",
abstract = "BACKGROUND. Inverted urothelial papilloma is an unusual neoplasm of the urinary tract. Although the association between inverted urothelial papilloma and urothelial carcinoma is not entirely dear, many studies indicate that patients with inverted papilloma are at increased risk for the development of urothelial carcinoma. In addition, aneuploid inverted papillomas have been associated with the subsequent development of urothelial carcinoma. The objective of this study was to determine whether ploidy, MIB-1 proliferative activity, or p53 protein staining in inverted papilloma were predictive of urothelial carcinoma. METHODS. Fifty-one cases of inverted papilloma were retrieved from the Tissue Registry of the Mayo Clinic. Clinical records were reviewed for patient age, length of follow-up, and history of urothelial carcinoma (defined as carcinoma prior to, concurrent with, or subsequent to the diagnosis of inverted papilloma). DNA ploidy analysis was determined using Feulgen stained sections from paraffin embedded tissues using an image analysis system. Quantitation of MIB-1 proliferative activity and p53 immunostaining was determined similarly using immunoperoxidase stained sections from paraffin embedded tissues. RESULTS. The mean age at diagnosis of inverted papilloma was 63.9 years (range, 37-87 years), and there were 39 men and 12 women. Patients were followed for a mean of 56.5 months (range, 1- 252 months). Tumors ranged in size from 02 to 4.3 cm (mean, 0.9 cm). Eight patients (15.7{\%}) had a prior, concurrent, or subsequent noninvasive World Health Organization and International Society of Urologic Pathology (WHO/ISUP) papillary neoplasm of low malignant potential or papillary, carcinoma of low grade (formerly WHO Grade 1 or 2 papillary urothelial carcinoma). Inverted papillomas in patients with a history of urothelial carcinoma were all diploid and had a mean MIB-1 activity of 6.3{\%} (range, 0.04-24.8{\%}) and mean p53 protein staining of 12.6{\%} (range, 0.5-24.9{\%}). These inverted papillomas ranged in size from 0.3 to 1.0 cm (mean, 0.5 cm). Inverted papillomas in patients without a history of urothelial carcinoma were aneuploid in 6 cases (14.3{\%}) and diploid in the remaining cases. These inverted papillomas had a mean MIB-1 activity of 1.6{\%} (range, 0.06-9.0{\%}) and mean p53 protein staining of 9.7{\%} (range, 0.05-38.0{\%}). Tumor size ranged from 0.2 to 4.3 cm (mean, 1.0 cm). There were no statistically significant differences in MIB-1 activity, p53 protein staining, ploidy, and morphologic features between inverted papillomas in patients with and without a history of urothelial carcinoma. CONCLUSIONS. Ploidy, MIB-1 proliferative activity, and p53 immunostaning in inverted urothelial papilloma were not useful in identifying patients who had a history of urothelial carcinoma.",
keywords = "Aneuploidy, Inverted urothelial papilloma, P53, Proliferation, Urothelial carcinoma",
author = "Cheville, {John C.} and Kevin Wu and Sebo, {Thomas J.} and Liang Cheng and Darren Riehle and Lohse, {Christine M.} and Pankratz, {V. Shane}",
year = "2000",
month = "2",
day = "1",
doi = "10.1002/(SICI)1097-0142(20000201)88:3<632::AID-CNCR21>3.0.CO;2-F",
language = "English (US)",
volume = "88",
pages = "632--636",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Inverted urothelial papilloma. Is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?

AU - Cheville, John C.

AU - Wu, Kevin

AU - Sebo, Thomas J.

AU - Cheng, Liang

AU - Riehle, Darren

AU - Lohse, Christine M.

AU - Pankratz, V. Shane

PY - 2000/2/1

Y1 - 2000/2/1

N2 - BACKGROUND. Inverted urothelial papilloma is an unusual neoplasm of the urinary tract. Although the association between inverted urothelial papilloma and urothelial carcinoma is not entirely dear, many studies indicate that patients with inverted papilloma are at increased risk for the development of urothelial carcinoma. In addition, aneuploid inverted papillomas have been associated with the subsequent development of urothelial carcinoma. The objective of this study was to determine whether ploidy, MIB-1 proliferative activity, or p53 protein staining in inverted papilloma were predictive of urothelial carcinoma. METHODS. Fifty-one cases of inverted papilloma were retrieved from the Tissue Registry of the Mayo Clinic. Clinical records were reviewed for patient age, length of follow-up, and history of urothelial carcinoma (defined as carcinoma prior to, concurrent with, or subsequent to the diagnosis of inverted papilloma). DNA ploidy analysis was determined using Feulgen stained sections from paraffin embedded tissues using an image analysis system. Quantitation of MIB-1 proliferative activity and p53 immunostaining was determined similarly using immunoperoxidase stained sections from paraffin embedded tissues. RESULTS. The mean age at diagnosis of inverted papilloma was 63.9 years (range, 37-87 years), and there were 39 men and 12 women. Patients were followed for a mean of 56.5 months (range, 1- 252 months). Tumors ranged in size from 02 to 4.3 cm (mean, 0.9 cm). Eight patients (15.7%) had a prior, concurrent, or subsequent noninvasive World Health Organization and International Society of Urologic Pathology (WHO/ISUP) papillary neoplasm of low malignant potential or papillary, carcinoma of low grade (formerly WHO Grade 1 or 2 papillary urothelial carcinoma). Inverted papillomas in patients with a history of urothelial carcinoma were all diploid and had a mean MIB-1 activity of 6.3% (range, 0.04-24.8%) and mean p53 protein staining of 12.6% (range, 0.5-24.9%). These inverted papillomas ranged in size from 0.3 to 1.0 cm (mean, 0.5 cm). Inverted papillomas in patients without a history of urothelial carcinoma were aneuploid in 6 cases (14.3%) and diploid in the remaining cases. These inverted papillomas had a mean MIB-1 activity of 1.6% (range, 0.06-9.0%) and mean p53 protein staining of 9.7% (range, 0.05-38.0%). Tumor size ranged from 0.2 to 4.3 cm (mean, 1.0 cm). There were no statistically significant differences in MIB-1 activity, p53 protein staining, ploidy, and morphologic features between inverted papillomas in patients with and without a history of urothelial carcinoma. CONCLUSIONS. Ploidy, MIB-1 proliferative activity, and p53 immunostaning in inverted urothelial papilloma were not useful in identifying patients who had a history of urothelial carcinoma.

AB - BACKGROUND. Inverted urothelial papilloma is an unusual neoplasm of the urinary tract. Although the association between inverted urothelial papilloma and urothelial carcinoma is not entirely dear, many studies indicate that patients with inverted papilloma are at increased risk for the development of urothelial carcinoma. In addition, aneuploid inverted papillomas have been associated with the subsequent development of urothelial carcinoma. The objective of this study was to determine whether ploidy, MIB-1 proliferative activity, or p53 protein staining in inverted papilloma were predictive of urothelial carcinoma. METHODS. Fifty-one cases of inverted papilloma were retrieved from the Tissue Registry of the Mayo Clinic. Clinical records were reviewed for patient age, length of follow-up, and history of urothelial carcinoma (defined as carcinoma prior to, concurrent with, or subsequent to the diagnosis of inverted papilloma). DNA ploidy analysis was determined using Feulgen stained sections from paraffin embedded tissues using an image analysis system. Quantitation of MIB-1 proliferative activity and p53 immunostaining was determined similarly using immunoperoxidase stained sections from paraffin embedded tissues. RESULTS. The mean age at diagnosis of inverted papilloma was 63.9 years (range, 37-87 years), and there were 39 men and 12 women. Patients were followed for a mean of 56.5 months (range, 1- 252 months). Tumors ranged in size from 02 to 4.3 cm (mean, 0.9 cm). Eight patients (15.7%) had a prior, concurrent, or subsequent noninvasive World Health Organization and International Society of Urologic Pathology (WHO/ISUP) papillary neoplasm of low malignant potential or papillary, carcinoma of low grade (formerly WHO Grade 1 or 2 papillary urothelial carcinoma). Inverted papillomas in patients with a history of urothelial carcinoma were all diploid and had a mean MIB-1 activity of 6.3% (range, 0.04-24.8%) and mean p53 protein staining of 12.6% (range, 0.5-24.9%). These inverted papillomas ranged in size from 0.3 to 1.0 cm (mean, 0.5 cm). Inverted papillomas in patients without a history of urothelial carcinoma were aneuploid in 6 cases (14.3%) and diploid in the remaining cases. These inverted papillomas had a mean MIB-1 activity of 1.6% (range, 0.06-9.0%) and mean p53 protein staining of 9.7% (range, 0.05-38.0%). Tumor size ranged from 0.2 to 4.3 cm (mean, 1.0 cm). There were no statistically significant differences in MIB-1 activity, p53 protein staining, ploidy, and morphologic features between inverted papillomas in patients with and without a history of urothelial carcinoma. CONCLUSIONS. Ploidy, MIB-1 proliferative activity, and p53 immunostaning in inverted urothelial papilloma were not useful in identifying patients who had a history of urothelial carcinoma.

KW - Aneuploidy

KW - Inverted urothelial papilloma

KW - P53

KW - Proliferation

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0034142361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034142361&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000201)88:3<632::AID-CNCR21>3.0.CO;2-F

DO - 10.1002/(SICI)1097-0142(20000201)88:3<632::AID-CNCR21>3.0.CO;2-F

M3 - Article

C2 - 10649258

AN - SCOPUS:0034142361

VL - 88

SP - 632

EP - 636

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -